Akron General's McDowell Cancer Center provides patients with access to care quickly. We also offer the newest therapies, diagnostics and surgical techniques to help minimize side effects and improve outcomes. A research site with national clinical trials, we offer treatment options that may help extend and improve lives. The McDowell Cancer Center is a member of six National Cancer Institute cooperative groups including: the American College of Radiology Imaging Network (ACRIN), American College of Surgeons Oncology Group (ACOSOG), Radiation Therapy Oncology Group (RTOG), Southwest Oncology Group (SWOG), National Surgical Adjuvant Breast and Bowel Project (NSABP), and the Gynecologic Oncology Group (GOG). We also participate in pharmaceutical and in-house investigator-initiated studies.
For more information about options available through our cancer center clinical trials, please contact the McDowell Cancer Center Research Department at 330-344-6348.
See below for active trials at the Akron General McDowell Cancer Center
Additional resources for cancer clinical trials.
National Institutes of Health, National Cancer Institute www.nci.nih.gov
Title(s):
CTSU CALGB 90601. A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
11026. A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
SWOG 0702. A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 1122. Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab with or without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 1205. Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
NSABP B-43. A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Investigator(s):
Andrew Fenton, MD
Contact
Information:
McDowell Cancer Research 330-344-6348
Title(s):
RTOG 1014. A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBrl) for Local Recurrence of Breast Carcinoma.
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
CTSU SCUSF 0806. Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (neo) Adjuvant Chemotherapy with Trastuzumab (Herceptin)
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
SWOG 1007. A Phase II Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
CTSU E2108. A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
SWOG 0812. A Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of High Dose Vitamin D in Premenopausal Women at High-Risk for Breast Cancer, Phase IIB
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
NSABP B-49. A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Investigator(s):
Andrew Fenton, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
SWOG 1105. Randomized Trial of Text-Messaging Intervention to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 1119. Phase II Randomized Study Of Whole Brain Radiotherapy In Combination With Concurrent Lapatinib In Patients With Brain Metastasis From HER2-Positive Breast Cancer- A COLLABORATIVE STUDY OF RTOG AND KROG.
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
SWOG 1207. Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 1005. A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
GOG 0263. Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy.
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG/GOG 0724. Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
CTSU CALGB 80702. A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 1010. A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
SWOG 1201. A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
GOG 0267. Quality of Life and Care Need in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
GOG 0235. A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
GOG 0213. A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
CTSU E1305. A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 1216. Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
CTSU E2906. Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age >= 60 Years)
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
CTSU E1505. A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>=4cm) - IIIA Non-Small Cell Lung Cancer
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
CTSU CALGB 30610. Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
SWOG 0819. A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 0937. Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
CTSU E5508. Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
CTSU E1609. A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
GOG 0261. A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 0848. A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
SWOG 1115. Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) VS mFOLFOX in Patients with Metastitic Pancreatic Cancer After Prior Chemotherapy NCI Version Date: 7/17/12
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348.
Title(s):
RTOG 0534. A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 0815. A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 0526. A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
CTSU CALGB 70807. The Men's Easting and Living (MEAL)Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 0622. A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer after Radical Prostatectomy.
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 0924. Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
EFC11785/PROSELICA Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m2 and at 25 mg/m2 Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen.
Investigator(s):
Esther Rehums, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
RTOG 1115. Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
Investigator(s):
Mitchel Fromm, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
Title(s):
SWOG 1014. Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
